Krishna Institute of Medical Sciences Share Price Target 2026 to 2030
Krishna Institute of Medical Sciences Ltd (KIMS) is one of the largest private healthcare providers in Andhra Pradesh and Telangana, offering multi-specialty tertiary and quaternary care across tier-1 and tier-2 cities. With a strong presence in high-demand medical segments like cardiology, neurology, oncology, and organ transplants, KIMS has grown rapidly through organic expansion and strategic acquisitions. However, its current valuation—trading at a P/E of over 84x—and rising debt levels warrant cautious optimism. This article provides a fact-based outlook and realistic share price targets for each year from 2026 to 2030.
Business: Multi-specialty hospital chain with ~4,000 beds across 10+ hospitals
Geography: Primarily Andhra Pradesh & Telangana; expanding into Karnataka and Maharashtra
Ownership: Promoter holding at 34.11% – led by Dr. Bhaskar Rao Bollineni and family
Listed: Yes – on BSE (543301) and NSE (KIMS) since August 2021
Clarifications:
Who owns KIMS? The Bollineni family (promoters) hold 34.11%; rest is held by institutions (DII + FII = 46.9%) and public.
Is KIMS listed? Yes – listed on August 4, 2021.
What was the IPO listing price? ₹281 per share (IPO price: ₹280).
Why is KIMS share price falling? Due to rich valuation (P/E >84x), rising debt (₹708 Cr), and profit-taking after a 300%+ rally since 2023.
Target price? Realistic 2026 range: ₹780–₹880 (see detailed breakdown below).
KIMS: Key Financial Snapshot
Metric
Value
Market Capitalization
₹24,686.57 Cr
Current Share Price
₹617
52-Week High / Low
₹798 / ₹474
P/E (TTM)
84.46
P/B (TTM)
10.78
Book Value (TTM)
₹57.24
EPS (TTM)
₹7.31
ROE
15.02%
ROCE
16.99%
Dividend Yield
0%
Debt
₹708 Cr
Cash Reserves
₹29.50 Cr
Sales Growth (YoY)
13.26%
Profit Growth (YoY)
28.73%
Shareholding Pattern
Category
Holding (%)
Promoters
34.11%
Domestic Institutions (DII)
32.61%
Public (Retail)
18.95%
Foreign Institutions (FII)
14.33%
Others
0%
Note: Promoter holding has declined from ~40% at IPO, raising mild governance concerns.
Krishna Institute of Medical Sciences(KIMS) Share Price Target Forecast (2026–2030)
Given the high P/E, strong profit growth, but modest ROE/ROCE, the upside is limited unless earnings accelerate further. Targets assume:
EPS CAGR of 20–22% (supported by 28.7% recent profit growth)
P/E compression from 84x to 50–55x by 2030
Debt management as a capex cycle peaks
Year
Target Price Range (₹)
2026
₹780 – ₹880
2027
₹840 – ₹960
2028
₹900 – ₹1,050
2029
₹960 – ₹1,140
2030
₹1,020 – ₹1,230
⚠️ Important: Even at ₹1,230 in 2030, P/E would be ~55x—still premium vs hospital peers like Apollo (P/E ~45x).
Year-wise Breakdown
Krishna Institute of Medical Sciences(KIMS) Share Price Target 2026
Year
Target 1
Target 2
2026
₹780
₹880
Rationale: Near-term upside supported by new hospital launches (Hyderabad, Bengaluru) and strong patient footfall. However, valuation caps aggressive moves.
Krishna Institute of Medical Sciences(KIMS) Share Price Target 2027
Year
Target 1
Target 2
2027
₹840
₹960
Rationale: Expected benefit from operational scale-up and higher occupancy rates. EBITDA margins may improve to 28–30%.
Krishna Institute of Medical Sciences(KIMS) Share Price Target 2028
Year
Target 1
Target 2
2028
₹900
₹1,050
Rationale: By 2028, debt/EBITDA could fall below 2x, supporting re-rating. ROCE may improve above 18% with asset utilization.
Krishna Institute of Medical Sciences(KIMS) Share Price Target 2029
Year
Target 1
Target 2
2029
₹960
₹1,140
Rationale: Long-term play on India’s private healthcare boom and medical tourism. Success depends on execution in new geographies.
Krishna Institute of Medical Sciences(KIMS) Share Price Target 2030
Year
Target 1
Target 2
2030
₹1,020
₹1,230
Rationale: The upper end assumes sustained 25%+ EPS growth, dividend initiation, and market leadership consolidation. Still, valuation remains rich.
Strengths vs Risks
✅ Strengths
Strong brand in South India with high patient loyalty
Expanding bed capacity and specialty services
Consistent 28%+ profit growth
High institutional ownership (47%)
⚠️ Risks
Extremely high P/E (84x) leaves little margin for error
Rising debt (₹708 Cr) from aggressive capex
No dividends – not suited for income investors
Promoter holding decline (from 40% → 34%)
Investment Suitability
Factor
Assessment
Risk Profile
High (premium healthcare stock)
Time Horizon
Long-term (5+ years)
Volatility
High
Dividend/Income
None (0% yield)
Ideal Investor
Growth-focused investor bullish on India’s private healthcare demand
FAQs
The Bollineni promoter family holds 34.11%; the rest is institutional and retail.
For 2026, a realistic range is ₹780–₹880. By 2030, it could reach ₹1,020–₹1,230.
Yes – listed on NSE & BSE since August 2021.
Due to valuation concerns, profit booking, and rising debt, not business deterioration.
IPO price was ₹280; listed at ₹281 on August 4, 2021.
Final Verdict
KIMS is a high-quality healthcare player with strong operational momentum, but its current valuation is stretched. While long-term demand for private healthcare in India remains robust, investors should expect moderate returns unless profitability accelerates further. Our 2026–2030 price targets (₹780–₹1,230) reflect steady appreciation—not speculative hype. Consider accumulating only on significant corrections.
📌 Disclaimer: Price targets are estimates based on current fundamentals and sector trends. They are not investment advice. Please consult a SEBI-registered advisor before investing.
Hi, I’m Raj Mittal, a stock market content writer focused on company analysis, share price trends, and fundamental research. I create simple, research-based insights to help investors make smarter market decisions.
